Rimegepant Works Well for Acute Migraine in Chinese Patients — First Real-World Study | Research

The takeaway

The first prospective real-world study of rimegepant in Chinese migraine patients found it effective for acute treatment with only 6% experiencing mild adverse events, including in patients who hadn't responded to other treatments.

6% adverse event rate
All mild — rimegepant showed favorable tolerability in the first Chinese real-world migraine study

What the researchers found

Rimegepant significantly reduced moderate-to-severe migraine pain and improved functional ability in Chinese patients, with effectiveness observed as early as 30 minutes and sustained through 48 hours. Only 6% experienced mild adverse events.

Why it matters

Most rimegepant clinical data comes from Western populations. This first prospective real-world study in Chinese patients confirms the drug's effectiveness and tolerability in an East Asian population, supporting its broader global use.

The numbers in context

This was a prospective real-world study — specific response rates were measured but the abstract focuses on the study design as a first-of-its-kind investigation.

How the study worked

Single-arm, prospective, real-world study of 133 enrolled participants (99 analyzed). Patients self-reported pain intensity, functional ability, and symptoms at predose and 0.5, 1, 2, 24, and 48 hours postdose via digital platform. Subgroups included prior nonresponders (n=30) and rimegepant+eptinezumab combination (n=23).

Who was studied

Chinese patients with migraine using rimegepant in a clinical setting

What this study cannot tell us

Single-arm design with no placebo control. Single attack evaluated per patient. Relatively small sample size. Self-reported outcomes may introduce bias. Registered retrospectively on ClinicalTrials.gov.

How to read the evidence

Moderate evidence — prospective real-world study with no placebo control, but provides valuable first data for this population.

When this study was published

Published in 2024 with data through November 2023, reflecting current rimegepant prescribing in China.

The bigger picture

CGRP-targeting therapies are transforming migraine treatment. Real-world evidence from diverse populations is essential for establishing these drugs' effectiveness beyond controlled clinical trials, and this study helps fill a significant gap for East Asian patients.

Questions still open

How does rimegepant compare to other acute migraine treatments like triptans in Chinese patients?
Would a larger, controlled study confirm the effectiveness seen in the prior nonresponder subgroup?
Is the combination of rimegepant and eptinezumab synergistic or simply additive for migraine management?

Common questions

Does rimegepant work for people who haven't responded to other migraine drugs?

Yes — this study included a subgroup of 30 prior nonresponders who still showed significant improvement with rimegepant, suggesting it works through a different enough mechanism to benefit patients who failed other treatments.

How quickly does rimegepant start working?

Patients reported improvement as early as 30 minutes after taking rimegepant, with continued improvement through 2 hours and sustained benefit up to 48 hours post-dose.

Read the original research

First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients.

The journal of headache and pain, 25(1), 160

View on PubMed ↗Publisher’s paper ↗

Citation

Yang, Zhao; Wang, Xiaodan; Niu, Mengyue; Wei, Qiao; Zhong, Huizhu; Li, Xiaoyan; Yuan, Weihong; Xu, Wenli; Zhu, Shuo; Yu, Shengyuan; Liu, Jun; Yan, Jianzhou; Kang, Wenyan; Huang, Peijian. (2024). First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients.. The journal of headache and pain, 25(1), 160. https://doi.org/10.1186/s10194-024-01873-5